James Westcott

James Westcott is the current CEO of ThirtyFiveBio, an early-stage drug discovery company focused on developing novel modulators for the treatment of serious digestive system diseases. Prior to their current role, James held various positions at Vertex Pharmaceuticals, including Director and Associate Director, where James led research efforts in areas such as renal disease, rare genetic diseases, immuno-oncology, and neurodegenerative therapeutic areas. James also has experience as a Research Scientist at BP and holds degrees in Chemistry and Applied Chemistry from the University of Bristol and Aston University, respectively.